See more : Nature’s Miracle Holding Inc. Common Stock (NMHI) Income Statement Analysis – Financial Results
Complete financial analysis of INmune Bio, Inc. (INMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of INmune Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Winstech Precision Holding Co., LTD. (001319.SZ) Income Statement Analysis – Financial Results
- Vox Valor Capital Limited (VOX.L) Income Statement Analysis – Financial Results
- Boise Cascade Company (BCC) Income Statement Analysis – Financial Results
- BKW AG (0QQ0.L) Income Statement Analysis – Financial Results
- Apax Global Alpha Limited (APAX.L) Income Statement Analysis – Financial Results
INmune Bio, Inc. (INMB)
About INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.27M | 17.07M | 20.54M | 5.92M | 3.28M | 1.11M | 435.36K | 101.50K | 0.00 |
| General & Administrative | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 195.47K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -146.60K |
| SG&A | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 48.87K |
| Other Expenses | 0.00 | -1.35M | -1.19M | 128.52K | 0.00 | 0.00 | -6.00 | 0.00 | 0.00 |
| Operating Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Cost & Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 77.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.74M | 25.95M | 29.15M | 12.23M | 9.30M | 12.44M | 981.48K | 227.49K | 195.47K |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 149.99K | -50.00K | 146.60K |
| EBITDA Ratio | 0.00% | -6,938.77% | -16,106.63% | -112,016.09% | -13.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.74M | -25.95M | -29.15M | -12.23M | -7.76M | -12.44M | -981.48K | -227.49K | -48.87K |
| Operating Income Ratio | -19,187.74% | -6,938.77% | -16,106.63% | -112,016.09% | -9.98% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -267.00K | -1.35M | -1.19M | 129.00K | 77.69K | 0.00 | 149.99K | -50.00K | 0.00 |
| Income Before Tax | -30.01M | -27.30M | -30.34M | -12.10M | -7.68M | -12.44M | -831.49K | -277.49K | -48.87K |
| Income Before Tax Ratio | -19,360.00% | -7,299.20% | -16,762.43% | -110,838.76% | -9.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.35M | -29.15M | -12.23M | 1.46M | -161.14K | -1.13M | -177.49K | 0.00 |
| Net Income | -30.01M | -28.65M | -30.34M | -12.10M | -9.14M | -12.44M | -831.49K | -277.49K | -48.87K |
| Net Income Ratio | -19,360.00% | -7,659.63% | -16,762.43% | -110,838.76% | -11.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| EPS Diluted | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
| Weighted Avg Shares Out (Dil) | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune...
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer...
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial...
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
“Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials” Webinar to be Held on November 7, 2024, at 1 PM ET.
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
Data from Animal Model Study Demonstrate XPro™ converts m icroglia from a demyelinating cell to a remyelinating cell
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial...
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that management...
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout 2025. It is said that the global metastatic castrate...
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC”...
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease...
Source: https://incomestatements.info
Category: Stock Reports